Suzhou AlphaV Biotech

AlphaV Biotech is a clinical-stage biotechnology company based in Suzhou, China, focused on developing next-generation vaccines and immunotherapies. The company utilizes a proprietary alphavirus vector platform, which is designed to deliver high levels of antigen expression and stimulate robust T-cell and B-cell immune responses. Its lead program, AV-001, is a COVID-19 vaccine candidate that has entered clinical trials, while other programs target HPV-related cancers and chronic Hepatitis B. By leveraging self-amplifying RNA technology within viral vectors, AlphaV Biotech aims to create more effective treatments for infectious diseases and oncology.